Three-Arm Study of the Safety and Efficacy of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis
Status:
Completed
Trial end date:
2008-11-10
Target enrollment:
Participant gender:
Summary
The objectives of this study are to assess the safety and efficacy of treatment with
pirfenidone 2403 milligrams per day (mg/d) compared with placebo in patients with idiopathic
pulmonary fibrosis (IPF), to assess the safety and efficacy of treatment with pirfenidone
1197 mg/d in patients with idiopathic pulmonary fibrosis and to characterize the
pharmacokinetic disposition of pirfenidone in patients with idiopathic pulmonary fibrosis.